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Abstract
Objective To estimate the absolute treatment effect of
statin therapy on major adverse cardiovascular events
(MACE; myocardial infarction, stroke and vascular death)
for the individual patient aged C70 years.
Methods Prediction models for MACE were derived in
patients aged C70 years with (n = 2550) and without
(n = 3253) vascular disease from the ‘‘PROspective Study
of Pravastatin in Elderly at Risk’’ (PROSPER) trial and
validated in the ‘‘Secondary Manifestations of ARTerial
disease’’ (SMART) cohort study (n = 1442) and the
‘‘Anglo-Scandinavian Cardiac Outcomes Trial-Lipid
Lowering Arm’’ (ASCOT-LLA) trial (n = 1893), respec-
tively, using competing risk analysis. Prespecified predic-
tors were various clinical characteristics including statin
treatment. Individual absolute risk reductions (ARRs) for
MACE in 5 and 10 years were estimated by subtracting on-
treatment from off-treatment risk.
Results Individual ARRs were higher in elderly patients
with vascular disease [5-year ARRs: median 5.1 %,
interquartile range (IQR) 4.0–6.2 %, 10-year ARRs: med-
ian 7.8 %, IQR 6.8–8.6 %] than in patients without vas-
cular disease (5-year ARRs: median 1.7 %, IQR
1.3–2.1 %, 10-year ARRs: 2.9 %, IQR 2.3–3.6 %). Ninety-
eight percent of patients with vascular disease had a 5-year
ARR C2.0 %, compared to 31 % of patients without vas-
cular disease.
Conclusions With a multivariable prediction model the
absolute treatment effect of a statin on MACE for indi-
vidual elderly patients with and without vascular disease
can be quantified. Because of high ARRs, treating all
patients is more beneficial than prediction-based treatment
for secondary prevention of MACE. For primary preven-
tion of MACE, the prediction model can be used to identify
those patients who benefit meaningfully from statin
therapy.
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Introduction
Vascular disease in the elderly (age C70 years) accounts
for a high global burden of disease as risk of atherosclerotic
vascular events and their case-fatality rate increase expo-
nentially with age [1–3]. Older patients who survive a
major adverse cardiovascular event (MACE) are com-
monly chronically disabled because of heart failure, car-
diac arrhythmia or neurologic deficits. Population aging
and the chronic complications of vascular events that
physicians encounter in the elderly have triggered a debate
about the benefit of cardiovascular risk management in
these patients. The ‘‘PROspective Study of Pravastatin in
Elderly at Risk’’ (PROSPER) trial found a 15 % reduction
in myocardial infarction, stroke and coronary heart disease
death with pravastatin treatment in elderly subjects [4].
Older patients are underrepresented in other trials evalu-
ating cardiovascular prevention strategies and it is, there-
fore, uncertain whether statins are effective in the elderly.
They have lower life-expectancy in general than middle-
aged individuals which could potentially limit their benefit
from statins. The benefit of statins is particularly uncertain
and debated in those with limited life expectancy due to
nonvascular diseases [5].
Statin therapy is recommended for the secondary pre-
vention of MACE in those who have vascular disease,
unless comorbidity and polypharmacy confound manage-
ment [6–8]. For the primary prevention of MACE, the
European guideline states that ‘statin therapy may be
considered particularly in the presence of at least one other
risk factor than age’ and the National Institute for Health
and Care Excellence (NICE) guideline advices statin
therapy in those with an estimated 10-year risk of
MACE C10 % [7, 9]. Since the QRISK2 score estimates a
10-year risk C10 % for every patient aged C70 years and
almost all older patients have at least one vascular risk
factor besides age, statin therapy would be indicated for
nearly all elderly patients [10]. However, under-prescrip-
tion of statins in daily practice may in part reflect uncer-
tainty about the extent to which elderly patients may
benefit from a statin [11]. As the absolute risk for vascular
disease and the absolute risk reduction (ARR) caused by a
statin are influenced by individual patient characteristics,
there is a potential range in the benefit received from a
statin. Therefore, we aimed to estimate the absolute treat-
ment effect of statin therapy on MACE for the individual
elderly patient by developing and validating a prediction
model based on individual patient characteristics [12, 13].
Materials and methods
Study populations
We developed two separate prediction models for MACE
in patients with and without vascular disease aged C70 -
years, since a history of vascular disease is the strongest
predictor for MACE in elderly subjects with great differ-
ences in risk profiles of elderly subjects with and without
vascular disease. Moreover, guidelines differentiate
between primary and secondary prevention of MACE
[6, 7]. Both models were derived in the PROSPER trial
population. The model for patients with vascular disease
was validated in the ‘‘Secondary Manifestations of
ARTerial disease’’ (SMART) cohort study and the model
for patients without vascular disease in the ‘‘Anglo-Scan-
dinavian Cardiac Outcomes Trial- Lipid Lowering Arm’’
(ASCOT-LLA) trial. The design and patient populations of
these studies have been described in detail in the original
publications [4, 14, 15]. Ethical approval was obtained for
these studies. The PROSPER study included patients
70–82 years of age from Scotland, Ireland and the
Netherlands with vascular disease or a high risk profile for
vascular disease between 1997 and 1999. Patients were
randomly assigned to 40 mg pravastatin per day or pla-
cebo. Patients from the elderly ASCOT-LLA population
recruited between 1998 and 2000 were 70–79 years of age
and were known to have hypertension (untreated or trea-
ted), but total cholesterol levels B6.5 mmol/l, in combi-
nation with three additional risk factors for vascular
disease. They originated from the United Kingdom, Ireland
and the Nordic Countries. Study participants were ran-
domly assigned to atorvastatin 10 mg or placebo. All
patients from the PROSPER and ASCOT-LLA trial were
not taking a statin at the time of study inclusion. Elderly
patients from the single-center prospective, observational
SMART cohort study with a history of vascular disease
from the Netherlands were 70–82 years of age and fol-
lowed up between 1996 and 2014.
Model derivation
We derived prediction models in the PROSPER trial for the
combined outcome of myocardial infarction, stroke and
vascular death (MACE) in elderly patients with (n = 2550)
and without (n = 3253) vascular disease. Vascular disease
included current or prior coronary artery disease (my-
ocardial infarction, angina, coronary artery bypass graft/
percutaneous coronary intervention), cerebrovascular dis-
ease (stroke or transient ischemic attack) or peripheral
artery disease (claudication or peripheral artery surgery).
We built a Fine & Gray competing risks model to account
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for nonvascular deaths [16]. Prespecified predictors from
existing risk scores in the elderly were: sex, age, current
smoking, diabetes, systolic blood pressure, low density
lipoprotein (LDL)-cholesterol, high-density lipoprotein
(HDL)-cholesterol, glomerular filtration rate (eGFR) and
number of medications taken [17–19]. Variable selection
was not applied to prevent optimism, which is the phe-
nomenon that a model optimally fits the data in which it is
derived, but is not generalizable to an external population.
Glomerular filtration rate was assessed with the Modifica-
tion of Diet in Renal Disease (MDRD) formula [20].
Polyvascular disease (vascular disease at C1 of the defined
locations) was added as a predictor to the model for
recurrent MACE. The number of medications per patient
was included as a measure of comorbidity, not taking into
account nasal sprays and topical skin medicines. Allocated
statin treatment was added to both models. Statin treatment
effect for secondary prevention of MACE was derived
from the PROSPER population. For primary prevention of
MACE, statin treatment effect was estimated in a pooled
analysis of the PROSPER and ASCOT trial population,
adjusted for potential study differences regarding statin
type, patient population and clinical setting. This was done
in a competing risks analysis of the pooled PROSPER and
ASCOT-LLA individual patient data, with statin treatment
and the trial patients originated from as independent vari-
ables. We singly imputed missing values by weighted
probability matching using multivariate regression, as
complete case analysis leads to loss of information and
possibly to bias of coefficients [21]. Missing values were
imputed for eGFR (n = 8, 0.1 %). Continuous predictors
were truncated at the 1st and 99th percentile to minimize
the influence of outliers in the model [22]. Whether the
association of continuous predictors with the outcome
variable was linear or not was assessed with restricted
cubic splines [23].
Model performance was assessed with the c-statistic
[95 % confidence interval (CI)] for discrimination and
with calibration plots of predicted versus observed risk.
The model was fitted for the prediction of 3.2-year risk
(median follow-up). These estimations were extrapolated
to derive 5-year and 10-year vascular event risks. An
individual 5-year and 10-year ARR was estimated for
each patient, by subtracting the predicted risk for a
specific patient with statin treatment from his or her
predicted risk without statin treatment (ARR = individual
MACE risk without a statin-individual MACE risk with a
statin). One can estimate the MACE risk and ARR with
and without statin treatment for each individual patient by
filling in patient characteristics in the model formula
(Table S1). This ARR can be translated into an individual
number needed to treat (iNNT), the number of patients
with the exact same risk profile needed to treat to prevent
1 event in 5 or 10 years, respectively (iNNT = 100/
ARR). For example, an estimated 5-year absolute risk
reduction of 2 % means that one has to treat 50 patients
with the exact same risk profile for 5 years to prevent 1
event [iNNT = 100/2 (ARR) = 50]. The distribution of
MACE risk and ARR in patients with and without vas-
cular disease is presented in a histogram and described as
median with an interquartile range (IQR).
Model validation
The derived model for patients with vascular disease was
externally validated in the SMART cohort study
(n = 1442) and the model for patients without vascular
disease in the ASCOT-LLA trial (n = 1893). Discrimina-
tion was assessed with the c-statistic (95 % CI) and cali-
bration with plots of predicted versus observed risk. To
optimally estimate vascular risk and treatment effect for
individual patients we adjusted for geographic differences
by recalibrating the models with updated cumulative
baseline hazard and mean linear predictor, while effect
sizes of predictors did not change. Missing values in the
ASCOT-LLA trial were imputed for creatinine (n = 54,
2.9 %), LDL-cholesterol (n = 185, 9.8 %) and number of
medications (n = 1156, 61 %). In the SMART study,
missing values were imputed for systolic blood pressure
(n = 11, 0.8 %), LDL-cholesterol (n = 37, 2.7 %), HDL-
cholesterol (n = 13, 0.9 %), eGFR (n = 4, 0.3 %) and
smoking (n = 10, 0.7 %). We estimated baseline LDL-c-
holesterol concentrations for patients in the SMART cohort
study who were already on a statin at the time of study
inclusion, according to the expected LDL-cholesterol
reduction that the different statin preparations with their
dosages probably had achieved [24].
Sensitivity analyses
We performed a sensitivity analysis to assess what the
expected individual ARR would be if patients were treated
with atorvastatin 20 mg as recommended by the NICE
guideline for primary prevention of vascular disease [9].
We assumed that atorvastatin 20 mg gives 6 % more LDL-
cholesterol reduction than pravastatin 40 mg or atorvas-
tatin 10 mg. In this scenario, the relative risk reduction
with a statin would be 25 % instead of 22 % for secondary
prevention and 15 % instead of 13 % for primary preven-
tion of vascular disease. In a second sensitivity analysis,
individual ARRs for primary prevention of MACE were
estimated with a combined statin relative risk reduction of
16 % for patients aged C75 years from different trial
populations [25].
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Net benefit analysis
The different treatment strategies (treating none, treating
all patients and treating patients according to the prediction
model with a statin) were compared with each other in a
net benefit analysis [26]. This method shows whether it is
valid to base treatment decisions on the prediction model.
Methods and results (Fig. S1, Table S2) can be found in the
Supplementary material.
Analyses were performed in R statistical software 3.2.0
with the add-on packages rms, plyr, pec, riskRegression,
and cmprsk (extended by Wolbers et al. [16]).
Results
Patient population and trial outcomes
The study population consisted of elderly patients with
vascular disease (PROSPER n = 2550, SMART
n = 1442) and patients without vascular disease (PROS-
PER n = 3253, ASCOT-LLA n = 1893). Baseline char-
acteristics are presented in Table 1. Mean age of patients
with vascular disease was 75.7 [standard deviation (SD)
3.4] years in the PROSPER trial and 73.6 (SD 2.7) years in
the SMART study. Mean age of patients without vascular
disease was 75.1 (SD 3.3) years in the PROSPER trial and
74.1 (SD 2.7) years in the ASCOT-LLA trial. During a
median follow-up of 3.2 years in patients with vascular
disease from the PROSPER trial, 517 MACE [68/1000
person years (PY)] and 114 nonvascular deaths occurred.
Median follow-up in SMART patients with vascular dis-
ease was 5.4 years with 398 MACE (46/1000 PY) and 212
nonvascular deaths. Patients without vascular disease from
the PROSPER trial experienced 395 MACE (39/1000 PY)
and 155 nonvascular deaths. In ASCOT-LLA patients
without vascular disease, median follow-up was 3.1 years
with 128 MACE (22/1000 PY) and 86 nonvascular deaths.
Model derivation and performance for patients
with vascular disease
The derived model in patients with vascular disease is
presented in Table 2A. Baseline systolic blood pressure
and LDL-cholesterol were exponentially related to the
outcome. LDL-cholesterol was not a major independent
predictor for MACE. There was no interaction present
between statin treatment and baseline risk, baseline LDL-
cholesterol, LDL-cholesterol after 3 months of randomi-
sation, age, renal function or polyvascular versus mono-
vascular disease (p values[0.2). Model performance in the
derivation set showed a good calibration (Fig. 1) and
moderate discrimination [c-statistic 0.62 (95 % CI
0.60–0.64)]. After recalibration, the model calibrated well
in the SMART validation set (Fig. 1) with a moderate
discriminative performance [c-statistic 0.60 (95 % CI
0.56–0.63)].
Model derivation and performance for patients
without vascular disease
The derived model for patients without vascular disease is
presented in Table 2B. Renal function (eGFR) was expo-
nentially related to the outcome. LDL-cholesterol was no
independent risk factor for MACE. There was no interac-
tion present between statin treatment and baseline risk,
baseline LDL-cholesterol, LDL-cholesterol after 3 months
of randomisation or age (p values[0.4). An interaction
between statin treatment and eGFR (p = 0.006) in the
derivation set was not present in the validation set and,
therefore, not included in the model. The model calibrated
well in the derivation set (Fig. 1) with a moderate dis-
criminative performance [c-statistic 0.61 (95 % CI
0.58–0.63)]. After recalibration, model calibration was
good in the ASCOT-LLA validation set (Fig. 1) with a low
discriminative performance [c-statistic 0.57 (95 % CI
0.53–0.63)].
Five-year and ten-year predicted absolute risk
for MACE and the absolute risk reduction if treated
with a statin
Figures 2 and 3 show the distribution of 5-year and 10-year
MACE risk and the absolute risk reductions in patients with
vascular disease from the PROSPER trial and SMART
study, and in patients without vascular disease from the
PROSPER and ASCOT-LLA trials. There was a wide dis-
tribution of MACE risk in patients with vascular disease (5-
year: median 26.4 %, IQR 20.3–33.6 %, 10-year: median
46.9 %, IQR 38.5–57.0 %) and in those without vascular
disease (5-year: median 13.7 %, IQR 10.4–17.8 %, 10-year:
median 25.5 %, IQR 19.8–32.4 %). Individual 5-year ARRs
with a statin were higher in patients with vascular disease
(median 5.1 %, IQR 4.0–6.2 %) than in patients without
vascular disease (median 1.7 %, IQR 1.3–2.1 %). Ninety-
eight percent of patients with vascular disease had a 5-year
ARR C2.0 % (iNNT B50), compared to 31 % of patients
without vascular disease. In patients with vascular disease
the median 10-year ARR was 7.8 % (IQR 6.8–8.6 %)
compared to a median 10-year ARR of 2.9 % (IQR
2.3–3.6 %) in patients without vascular disease.
Sensitivity analyses
Under the assumption that atorvastatin 20 mg lowers LDL-
cholesterol with an additional 6 % compared to pravastatin
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40 mg or atorvastatin 10 mg, the median 5-year ARR
would be 6.0 % (IQR 4.7–7.3 %) in patients with vascular
disease and 2.0 % (IQR 1.5–2.5 %) in patients without
vascular disease. Forty-nine percent of patients without
vascular disease would have a 5-year ARR C2.0 %.
Median 10-year ARR would be 9.3 % (IQR 8.1–10.2 %)
for patients with vascular disease and 3.5 % (IQR
2.8–4.2 %) for patients without vascular disease.
Assuming statin therapy reduces MACE by 16 % in
patients without vascular disease, the median 5-year ARR
would be 2.1 % (IQR 1.6–2.6 %) and the median 10-year
ARR would be 3.6 % (IQR 2.9–4.4 %). Fifty-three percent
of patients without vascular disease would have a 5-year
ARR C2.0 %.
Discussion
Risk for MACE and the absolute treatment effect of a statin
on MACE for individual elderly patients can be estimated
with a clinical prediction model containing simple, readily
available patient characteristics. There is a wide distribu-
tion of MACE risk in elderly patients with and without
vascular disease. For secondary prevention of MACE,
treating all patients is most beneficial since predicted
absolute risk reductions are almost invariably high. With
the use of a prediction model that quantifies an individual’s
expected absolute risk reduction by statin treatment, those
who benefit meaningfully from statin therapy in absolute
terms in the primary prevention setting can be identified.
Table 1 Baseline characteristics of elderly patients (age C70 years) with and without vascular disease
With vascular disease Without vascular disease
PROSPER
(n = 2550)
SMART
(n = 1442)
PROSPER
(n = 3253)
ASCOT-LLA
(n = 1893)
Demographics
Male gender (n, %) 1453 (57.0) 1062 (73.7) 1350 (41.5) 1525 (80.6)
Age (years) 75.7 (3.4) 73.6 (2.7) 75.1 (3.3) 74.1 (2.7)
Country of residence (n, %)
Scotland/UKa 1232 (48.3) 1288 (39.6) 990 (52.3)
Ireland 845 (33.1) 1338 (41.1) 19 (1.0)
The Netherlands 473 (18.5) 1442 (100) 627 (19.3)
Denmark 133 (7.0)
Finland 126 (6.7)
Iceland 11 (0.6)
Norway 205 (10.8)
Sweden 409 (21.6)
Current smoker (n, %) 474 (18.6) 238 (16.5) 1084 (33.3) 402 (21.2)
N medications (median, IQR) 4 (3–6) 5 (4–7) 3 (2–4) 2 (1–3)
Statin treatment (n, %) 1299 (50.9) 885 (61.4) 1591 (48.9) 939 (49.6)
Medical history
Diabetes (n, %) 224 (8.7) 293 (20.3) 399 (12.3) 514 (27.2)
Cardiovascular disease (n, %)
Coronary artery disease 1524 (59.8) 610 (42.3) 0 (0) 0 (0)
Cerebrovascular disease 425 (16.7) 276 (19.1) 0 (0) 0 (0)
Peripheral artery disease 206 (8.1) 238 (16.5) 0 (0) 0 (0)
Polyvascular disease 395 (15.5) 318 (22.1) 0 (0) 0 (0)
Physical examination
Heart rate (beats/min) 65.2 (11.6) 66.0 (14.1) 67.2 (11.6) 69.6 (12.3)
Systolic blood pressure (mmHg) 152 (22) 148 (22) 157 (22) 170 (19)
Laboratory measurements
LDL cholesterol (mmol/l) 3.8 (0.8) 3.8 (1.2) 3.8 (0.8) 3.5 (0.7)
HDL cholesterol (mmol/l) 1.2 (0.3) 1.3 (0.4) 1.3 (0.4) 1.3 (0.4)
eGFR (ml/min/1.73 m2) 58.8 (14.3) 66.8 (16.7) 61.0 (14.7) 63.6 (11.8)
Data are displayed as mean (SD) unless indicated otherwise
a UK United Kingdom
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Current guidelines recommend statin treatment for the
secondary prevention of MACE in general, but where
possible treatment decisions should ideally be made per
individual taking into account expected absolute treatment
effect, adverse events and patient preferences [6–8]. High
absolute treatment effects found in our study underline this
recommendation, and moreover enable physicians to esti-
mate the individual absolute treatment effect for a patient.
There seems to be a maximal absolute risk reduction that
can be achieved by a statin in this high-risk population, as a
statin may delay recurrent MACE in patients at very high
risk (C70 % 10-year MACE risk) rather than prevent it
from happening during a lifetime. In these individuals, the
benefit from statin therapy in recurrent MACE-free life
years might be limited. In general, treating elderly patients
with vascular disease with a statin seems beneficial as the
large expected benefits are very likely to outweigh poten-
tial harms. These include adverse events like myopathy and
incident type 2 diabetes, drug–drug interactions and the
inconvenience of polypharmacy which impair quality of
life in elderly patients in particular [27, 28]. An example of
a drug–drug interaction that increases the risk of adverse
events comes from the United States of America where
83 % of patients with dyslipidemia is treated with a
CYP3A4-metabolized statin of whom 25–30 % concomi-
tantly use a CYP3A4-inhibitor [29]. Even though there
might be a higher risk of serious adverse events in the
elderly, there is no conclusive evidence for a higher inci-
dence of rhabdomyolysis, cognitive deterioration, liver or
kidney injury [30].
For primary prevention of vascular disease, current
guidelines advise to treat those at high risk which means
that practically everyone aged C70 years would be given a
statin since age dominates risk scores [6, 7, 9]. However, in
clinical practice statin treatment rates for elderly patients
are low presumably reflecting ambiguities about the abso-
lute benefit of statin treatment for the primary prevention of
vascular disease in the elderly [11]. Moreover, the inci-
dence of severe comorbidities increases with age and
emphasis might be placed on treating these inter-current
Table 2 Fitted prediction
models for major adverse
cardiovascular events in elderly
patients
Variable Coefficient sHR (95 % CI) p value
A. Patients with vascular disease
Male sex 0.401 1.49 (1.21–1.84) \0.001
Age (years) 0.042 1.04 (1.02–1.07) 0.002
Current smoking 0.240 1.27 (1.02–1.58) 0.031
Diabetes 0.543 1.72 (1.31–2.26) \0.001
Polyvascular disease 0.344 1.41 (1.13–1.76) 0.003
Number of medications 0.053 1.06 (1.01–1.10) 0.009
Systolic blood pressure (per 10 mmHg) -0.366 0.084
Systolic blood pressure (per 10 mmHg)2 0.001 0.084
LDL-cholesterol (mmol/l) 0.876 0.074
LDL-cholesterol (mmol/l)2 -0.109 0.080
HDL-cholesterol (mmol/l) 0.081 1.08 (0.82–1.43) 0.570
eGFR (per 10 ml/min/1.73 m2) -0.053 0.95 (0.88–1.02) 0.150
Statin treatment -0.245 0.78 (0.66–0.93) 0.006
B. Patients without vascular disease
Male sex 0.283 1.33 (1.06–1.66) 0.013
Age (years) 0.037 1.04 (1.01–1.07) 0.018
Current smoking 0.290 1.34 (1.07–1.68) 0.012
Diabetes 0.210 1.23 (0.93–1.64) 0.150
Number of medications 0.090 1.09 (1.05–1.15) \0.001
Systolic blood pressure (per 10 mmHg) 0.060 1.06 (1.01–1.11) 0.014
LDL-cholesterol (mmol/l) 0.007 1.01 (0.89–1.15) 0.920
HDL-cholesterol (mmol/l) -0.359 0.70 (0.51–0.96) 0.028
eGFR (per 10 ml/min/1.73 m2) -0.613 0.008
eGFR (per 10 ml/min/1.73 m2)2 0.005 0.008
Statin treatment -0.140 0.87 (0.73–1.03) 0.110
Models derived with Fine and Gray competing risk analysis
sHR subdistribution hazard ratio, CI confidence interval
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illnesses. Our prediction model shows that the absolute
effect of a statin on MACE is influenced by individual
patient characteristics. With the use of this prediction
model those individuals who benefit most from statin
treatment can be identified. A patient’s advantage of statin
therapy in terms of reduction of absolute MACE risk can
be estimated and weighed against potential harms of
treatment and the costs of statin therapy, even though these
are low, in making a treatment decision. A potential harm
of statin therapy found in the PROSPER trial was an
increase in cancer incidence [4]. However, a meta-analysis
of 35 large randomised controlled trials found an equal risk
of cancer in those with and without statins [31]. Even so,
there was no increased cancer risk in statin users during the
extensive 8–11 year follow-up of both the PROSPER and
ASCOT-LLA trial [32, 33]. In patients aged[70 years
from the ASCOT-LLA population (n = 2415), atorvastatin
did not raise cancer risk (sHR 0.83, 95 % CI 0.58–1.20).
Therefore, it is likely that statin therapy does not increase
cancer incidence. For adequate estimations of MACE risk
and the absolute risk reduction with a statin, death due to
cancer was taken into account as a competing event.
Apart from the estimation of individual absolute statin
treatment effects, these models inform physicians and
Fig. 1 Calibration plots of predicted versus observed MACE risk in elderly patients
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Fig. 2 Distribution of 5-year absolute risk for MACE and the absolute risk reduction with statin therapy in elderly patients
Fig. 3 Distribution of 10-year absolute risk for MACE and the absolute risk reduction with statin therapy in elderly patients
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patients about an individual’s 5-year or 10-year risk for
MACE. Thereby the need for preventive medical and life-
style interventions could be established. Informing patients
about their risk and engaging them in treatment decision-
making might stimulate treatment adherence [34]. Vascular
risk estimation in elderly patients has been challenging and
the Systematic Coronary Risk Evaluation (SCORE),
QRISK2 and Framingham/Pooled Cohort Equations risk
charts are not validated for patients[65 years,[74 years
and[79 years of age, respectively [10, 35, 36]. Further-
more, they do not take into account that many elderly
patients die from a nonvascular cause. One risk score for
patients aged C65 years accounted for competing events
like the risk score in this study, but that study included only
patients without vascular disease and the outcome was
coronary artery events instead of MACE as in this study
[17]. Interestingly, LDL-cholesterol was a weak predictor
for MACE in both patients with and without vascular
disease. Other risk factors contribute more to risk predic-
tion in the elderly. As our aim was to predict individual
absolute benefit from statin therapy we did not assess
causality. Previous studies showed no or an inverse asso-
ciation between LDL-cholesterol and all-cause mortality
[37]. In the PROSPER trial pravastatin lowered MACE risk
with 15 % whereas it had no effect on all-cause mortality,
which implies that the causal association between LDL-
cholesterol and MACE may differ from the association
between LDL-cholesterol and mortality.
Strengths and limitations
A strength of this study is that the prediction models were
derived and externally validated in an elderly population.
Moreover, the variable ‘number of medications’ was added
to the models as a proxy for comorbidity [38, 39]. Also, we
accounted for competing events (death due to a nonvas-
cular cause) in our statistical analysis. Furthermore, the
model for those with vascular disease was validated in a
patient population from a cohort study. Thereby, we show
that our model is generalizable to a broad elderly popula-
tion and not restricted to relatively healthy patients in trials.
There are some limitations of this study. Overall discrim-
inative ability of these models was moderate, and low in
the ASCOT-LLA population. This could be explained by
the homogeneity of trial populations in general and of the
ASCOT-LLA population in particular with a small range in
MACE risk [40]. The adequate calibration of these models
may be more important in assessing model validity, as we
aim to accurately predict MACE risk and the absolute
statin treatment effect for the individual elderly patient. In
the PROSPER and ASCOT-LLA trial, fixed statin doses
were given and dosing was not titrated to a specific LDL-
cholesterol target. Patients in the SMART study used
different statins and dosages. It could be that treatment
effects for more potent statins or dosages are underesti-
mated with the current model [41]. In sensitivity analyses
we established what the individual absolute risk reduction
might be with atorvastatin 20 mg or the treatment effect
from a meta-analysis in elderly subgroups from statin trials.
These results should be interpreted with caution as the
meta-analysis was performed in slightly older patients
(C75 years) for an LDL-reduction of 1 mmol/l, for a dif-
ferent vascular outcome and not taking competing risks
into account [25]. Finally, our results cannot be extrapo-
lated to the very old (C85 years) and to patients with
chronic kidney disease stage IV or V (eGFR\30 ml/min),
since they were not enrolled in these studies.
Conclusions
A multivariable prediction model can be used to quantify
the absolute MACE risk and absolute MACE risk reduction
in 5 and 10 years by statin therapy in individual elderly
patients with and without vascular disease. Most elderly
patients with vascular disease have high predicted absolute
MACE risk reduction by a statin and it is most beneficial to
treat them all with a statin for secondary prevention of
vascular disease. The prediction model identifies the
elderly patients who benefit most (i.e., meaningfully in
terms of ARR) from statin therapy for primary prevention
of MACE. The model could help physicians in managing
vascular risk in their elderly patients, a population rapidly
rising in prevalence.
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